Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.56 |
| ▸ | SRC | P12931 | 8/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319702 | 0.87 | PDGFRB (0.45) | ABL1SRCKITLMNAALDH1A1 | |
| SCHEMBL3319309 | 0.84 | ABL1 (0.62) | ABL1SRCKITLMNAKDM4E | |
| SCHEMBL4472421 | 0.81 | ABL1 (0.60) | ABL1SRCKIT | |
| SCHEMBL4925656 | 0.81 | KIT (0.56) | ABL1SRCKIT | |
| SCHEMBL3319441 | 0.78 | ABL1 (0.59) | ABL1SRCKITKDM4ENPC1 | |
| SCHEMBL2982155 | 0.78 | CHEK1 (0.43) | KITSYK | |
| SCHEMBL2978828 | 0.77 | KIT (0.50) | ABL1SRCKITLMNAKDM4E | |
| SCHEMBL2974049 | 0.76 | BTK (0.49) | ABL1SRCKIT | |
| SCHEMBL16602983 | 0.75 | ABL1 (0.66) | ABL1SRCKITLMNAKDM4E | |
| SCHEMBL4465247 | 0.75 | KIT (0.52) | ABL1SRCKITALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776878-B2 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-13 | — | — | US | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| US-7776878-B2 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | ABL1 698/4885SRC 1484/4885KIT 4462/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | ABL1 746/4885SRC 1586/4885KIT 4492/4885 |
| US-20100120840-A1 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents | CYP3A5, ABCB1, CYP3A43 | ABL1 442/4885SRC 2766/4885KIT 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.